🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Current status of ADCs in #lymphoma #DLBCL. Loved developing this invited piece with two lymphoma rising stars Gulrayz Ahmed & Taha A, MD MCW Cancer Center #lymsm tandfonline.com/doi/full/10.10…

The 2-year progression-free survival of 72% compares favorably with previously reported outcomes with chemoimmunotherapy in TP53-mutant MCL. ow.ly/IzRJ50UQIvO #clinicaltrialsandobservations #lymphoidneoplasia

When reports emerged in 2023 of T cell secondary malignancies in CAR-T treated pts, mechanism was unclear. New MSKCC report NEJM describes LV construct integration into TP53. Likely v rare event but does inform debate about using CAR-T early vs later. nejm.org/doi/full/10.10…

Asciminib for Ph+ ALL: a step forward? ow.ly/EGJJ50UVnf1 #clinicaltrialsandobservations

Menin inhibitors in the treatment of acute myeloid leukemia ow.ly/QQcY50UVnwL #bloodspotlight #myeloidneoplasia

It is important to be aware of this unusual presentation and blastoid morphology to avoid the misdiagnosis of acute lymphoblastic leukemia, as these conditions differ in their treatment approach and prognosis. ow.ly/OSkG50V3JuB #bloodwork #lymphoidneoplasia

IMPROVE RCT results 🤩🧐 NO evidence that pausing BTKi for 3 weeks helps improve antibody responses to 💉 in #CLL. Thread of findings 👇 Huge thanks to patients, fantastic nhs colleagues and National Institute for Health and Care Research College of Medicine and Health (UoB) University Hospitals Birmingham for efforts to deliver this thelancet.com/journals/lanha…

Venetoclax in combination with a pediatric-inspired regimen for the treatment of newly diagnosed adults with Philadelphia chromosome-negative acute lymphoblastic leukemia haematologica.org/article/view/h… #leusm #ALL

If B cell lymphomas had a calendar today 📆 … 05/05/20 25  😉 a #hemepath #CincoDeMayo #MetGala post 📍CLL (CD5) 📍Mantle cell lymphoma (CD5) 📍DLBCL (CD20) 📍Hairy cell leukemia (CD25) #Nerdy…. I admit 🤓 even for a pathologist! 🙈 #IYKYK

Peripheral T- and natural killer-cell lymphomas: ESMO–EHA Clinical Practice Guideline for diagnosis, treatment and follow-up☆ - Annals of Oncology annalsofoncology.org/article/S0923-…

Just out Blood Advances Zanubrutinib in patients who didn't tolerate ibrutinib or acalabrutinib. Updated results. pubmed.ncbi.nlm.nih.gov/40334067/ #CLL Jeff Sharman Fred Hutch Cancer Center

🚨 Management of relapsed or refractory large B-cell lymphoma: A British Society for Haematology Guideline Full text here: buff.ly/fIxuSNz BSH - Haematology Sridhar Chaganti Bernard Maybury Chris Fox Toby Eyre Kate Cwynarski

Nivolumab-AVD Versus Brentuximab Vedotin–AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826 | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JC…

#18ICML Big Debate: CNS prophy in DLBCL - Dr. Ferreri argues CNS relapse with v poor survival & suboptimal salvage options - He argues HD-MTX benefit outweighs toxicity, especially for high-risk EN sites - in his center experience, no CNS relapses with HD-MTX #lymsm 1/

🚨🚨We are pleased to publish the next output via the HoLISTIC consortium (Hodgkin Lymphoma International STudy for Individual Care: hodgkinconsortium.com): The E-HIPI (Early-Stage Hodgkin International Prognostic Index) prediction model for early-stage Hodgkin lymphoma. 1/9🧵

Lucky to have a supportive work family Banner MD Anderson while mine is growing

Advances in Lymphoma: Report from ASCO and EHA 2025 youtu.be/cBIEnUZF97g?si… via YouTube Watch my #HealthcareUnfiltered conversation with Pallawi Torka of Memorial Sloan Kettering Cancer Center out now. Join the conversation on what’s new in lymphoma from #ASCO25 and #EHA25